ArticleTransplant international : official journal of the European Society for Organ Transplantation2026
Comparable outcomes with anti-thymocyte globulins versus basiliximab in kidney transplantation from controlled circulatory death donors.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to organ shortage, donation after circulatory death (DCD) has increased. As DCD kidney grafts have higher rates of delayed graft function (DGF), the French national protocol mandates the use of hypothermic machine perfusion and routine anti-thymocyte globulin (ATG) induction therapy. However, evidence favoring ATG over interleukin-2 receptor antagonists, such as basiliximab, remains scarce. We retrospectively analysed a single-center cohort of 158 low immunological risk patients who underwent DCD kidney transplantation between 2015 and 2023. Patients transplanted before March 2020 received ATG (n = 64), while those transplanted thereafter (during and after the COVID-19 pandemic) received basiliximab (n = 94). Baseline characteristics were comparable, except for recipient age (lower in the basiliximab group), and cold ischemia times were similar. There were no differences in primary non-function, DGF rates (17% after ATG versus 12% after basiliximab), biopsy-proven rejection, one-year renal function or graft survival. ATG was associated with prolonged EBV and BK viremia without increased complications. Hospital stays were similar, but ATG induction was 1.7 times more expensive. These findings were confirmed in an independent French multicenter cohort (n = 506). In conclusion, basiliximab appears to be a cost-effective alternative to ATG for low-immunological-risk patients receiving DCD kidney grafts, for whom ATG is not clearly indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.